Valuation: Adial Pharmaceuticals, Inc.

Market Cap 6M 5.25M 4.84M 4.46M 8.41M 578M 8.6M 57.85M 22.75M 283M 22.54M 22.05M 975M P/E 2026 *
-
P/E 2027 * -0.2x
Enterprise Value 6M 5.25M 4.84M 4.46M 8.41M 578M 8.6M 57.85M 22.75M 283M 22.54M 22.05M 975M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
95.68%
Yield 2026 *
-
Yield 2027 * -
1 day+0.36%
1 week+0.72%
Current month+9.38%
1 month+7.69%
3 months+71.78%
6 months-50.22%
Current year-49.09%
1 week 2.6
Extreme 2.6
2.94
1 month 2.32
Extreme 2.325
2.98
Current year 1.31
Extreme 1.31
6.75
1 year 1.31
Extreme 1.31
18.9
3 years 1.31
Extreme 1.31
221.88
5 years 1.31
Extreme 1.31
3,175
10 years 1.31
Extreme 1.31
5,900
Manager TitleAgeSince
Chief Executive Officer 66 2022-08-17
Director of Finance/CFO 63 2024-11-15
Chief Operating Officer 61 2024-01-17
Director TitleAgeSince
Director/Board Member 76 2015-01-31
Director/Board Member 46 2014-08-31
Chairman 58 2022-08-17
Date Insider Type Main position Quantity % Market Cap.
6/12/26 Buy

Director

36,378 1.6970%
4/7/26 Free

Director

9,185 0.6432%
4/7/26 Free

Chief Operating Officer

26,510 1.8565%
Change 5-day change 1-year change 3-year change Capi.($)
+0.36%+0.72%-75.18%-98.46% 6M
-1.29%-3.11%-0.35%+3.09% 49.18B
+3.90%-0.39%+386.06%+593.85% 39.58B
-1.70%+4.46%+5.93%+60.25% 34.69B
-2.01%-0.76%+28.41%-8.01% 34.42B
+0.06%+0.34%+2.38%+34.38% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+72.42%+115.55% 15.36B
+1.12%+1.91%+14.54%+19.16% 14.05B
0.00%+1.36%+18.43%-30.79% 13.02B
Average +0.09%+0.10%+50.29%+76.56% 24.36B
Weighted average by Cap. -0.05%-0.18%+79.44%+123.31%

Financials

2026 *2027 *
Net sales - -
Net income -15.5M -13.54M -12.5M -11.52M -21.71M -1.49B -22.19M -149M -58.74M -731M -58.19M -56.91M -2.52B -26.15M -22.85M -21.09M -19.44M -36.64M -2.52B -37.45M -252M -99.14M -1.23B -98.21M -96.05M -4.25B
Net Debt - -
Logo Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc. is a biopharmaceutical company. Its lead program is AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis. AT177 is a fully synthetic, patented, oral AhR agonist designed to restore mucosal immune homeostasis at the site of disease with minimal systemic exposure. AT177's active ingredient is a prodrug of indirubin, a potent AhR agonist within indigo naturalis, a botanical extract with clinical efficacy in ulcerative colitis. AT177's colon-targeted formulation delivers therapeutic AhR engagement directly to the colonic mucosa with exquisite gut restriction, minimizing the systemic AhR exposure associated with adverse effects. Its historical investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder in heavy drinking patients.
Employees
5
Date Price Change Volume
26-07-17 US$2.800 +0.36% 36,438
26-07-16 US$2.790 +2.57% 15,541
26-07-15 US$2.720 +2.64% 5,906
26-07-14 US$2.650 -6.36% 65,831
26-07-13 US$2.830 +1.80% 53,046
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
2.800USD
Average target price
7.000USD
Spread / Average Target
+150.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADIL Stock